In a rapidly evolving pharmaceutical landscape shaped by artificial intelligence, regulatory change, commercialization pressures, and increasing volatility, uncertainty, complexity, and ambiguity (VUCA), this keynote will highlight the strategic value of Primary Competitive Intelligence (CI). The session will examine how primary CI, grounded in direct and actionable real-world insights, can support timely strategic adjustments, strengthen decision-making, and enhance competitive advantage across the entire product lifecycle, from early-stage assessment through late lifecycle management.
Attendees will gain a practical understanding of how to effectively integrate primary CI into strategic planning and execution. The presentation will further demonstrate how deeper insights, generated through a structured four-pronged methodology, can translate into measurable business impact and sustainable strategic advantage.
